Page 126 - 《中国药房》2022年12期

药物监测[J].中国感染与化疗杂志，2021，21（3）：275- 50：69-76.
281. [39] NIKOLOS P，OSORIO J，MOHRIEN K，et al. Pharmaco-
[27] LUQUE S，MUÑOZ-BERMUDEZ R，ECHEVERRÍA-ESNAL kinetics of linezolid for methicillin-resistant Staphylococ-
D，et al. Linezolid dosing in patients with liver cirrhosis： cus aureus pneumonia in an adult receiving extracorporeal
standard dosing risk toxicity[J]. Ther Drug Monit，2019， membrane oxygenation[J]. Am J Health Syst Pharm，
41（6）：732-739. 2020，77（11）：877-881.
[28] CHENG C N，LIN S W，WU C C. Early linezolid-associ- [40] BLASSMANN U，ROEHR A C，FREY O R，et al.
ated lactic acidosis in a patient with Child’s class C liver Decreased linezolid serum concentrations in three criti-
cirrhosis and end stage renal disease[J]. J Infect Chemo- cally ill patients：clinical case studies of a potential drug
ther，2018，24（10）：841-844. interaction between linezolid and rifampicin[J]. Pharma-
[29] KIM H S，LEE E，CHO Y J，et al. Linezolid-induced cology，2016，98（1/2）：51-55.
thrombocytopenia increases mortality risk in intensive [41] OKAZAKI F，TSUJI Y，SETO Y，et al. Effects of a rifam-
care unit patients，a 10 year retrospective study[J]. J Clin picin pre-treatment on linezolid pharmacokinetics[J]. PLoS
Pharm Ther，2019，44（1）：84-90. One，2019，14（9）：e0214037.
[30] SOUZA E，CRASS R L，FELTON J，et al. Accumulation [42] ROGER C，MULLER L，WALLIS S C，et al. Population
of major linezolid metabolites in patients with renal pharmacokinetics of linezolid in critically ill patients on
impairment[J]. Antimicrob Agents Chemother，2020，64 renal replacement therapy：comparison of equal doses in
（5）：e00027-e00020. continuous venovenous haemofiltration and continuous
[31] CHENG C N，WU C C，KUO C H，et al. Impact of high venovenous haemodiafiltration[J]. J Antimicrob Chemother，
plasma concentrations of linezolid in Taiwanese adult 2016，71（2）：464-470.
patients-therapeutic drug monitoring in improving adverse [43] ZHENG J B，SUN Z D，SUN L，et al. Pharmacokinetics
drug reactions[J]. J Formos Med Assoc，2021，120（1 Pt 2）： and pharmacodynamics of linezolid in patients with sepsis
466-475. receiving continuous venovenous hemofiltration and
[32] HANAI Y，MATSUO K，OGAWA M，et al. A retrospec- extended daily hemofiltration[J]. J Infect Dis，2020，221
tive study of the risk factors for linezolid-induced throm- （Suppl 2）：S279-S287.
bocytopenia and Anemia[J]. J Infect Chemother，2016，22 [44] DONG H Y，XIE J，WANG T T，et al. Pharmacokinetic/
（8）：536-542. pharmacodynamic evaluation of linezolid for the treat-
[33] CRASS R L，COJUTTI P G，PAI M P，et al. Reappraisal ment of staphylococcal infections in critically ill pa-
of linezolid dosing in renal impairment to improve safe- tients[J]. Int J Antimicrob Agents，2016，48（3）：259-264.
ty[J]. Antimicrob Agents Chemother，2019，63（8）： [45] 陈杏凯，张海霞.蒙特卡罗模拟评价中国成人患者的利奈
e00605-e00619. 唑胺给药方案[J].药学与临床研究，2020，28（5）：345-
[34] ZHANG S H，ZHU Z Y，CHEN Z，et al. Population phar- 348.
macokinetics and dosage optimization of linezolid in [46] WU X F，TANG Y，ZHANG X H，et al. Pharmacokinetics
patients with liver dysfunction[J]. Antimicrob Agents Che- and pharmacodynamics of linezolid in plasma/cerebrospi-
mother，2020，64（6）：e00133-e00120. nal fluid in patients with cerebral hemorrhage after lateral
[35] SARTORI M，LOREGIAN A，PAGNI S，et al. Kinetics of ventricular drainage by Monte Carlo simulation[J]. Drug
linezolid in continuous renal replacement therapy：an in Des Devel Ther，2018，12：1679-1684.
vitro study[J]. Ther Drug Monit，2016，38（5）：579-586. [47] BALANDIN B，LOBO B，ORDEN B，et al. Emergence of
[36] HIRAIWA T，MORIYAMA K，MATSUMOTO K，et al. In linezolid-resistant coagulase-negative staphylococci in an
vitro evaluation of linezolid and doripenem clearance with intensive care unit[J]. Infect Dis（Lond），2016，48（5）：
different hemofilters[J]. Blood Purif，2020，49（3）：295- 343-349.
301. [48] MATRAT L，PLAISANT F，BARRETO C，et al. Increa-
[37] VILLA G，DI MAGGIO P，DE GAUDIO A R，et al. sing use of linezolid in a tertiary NICU during a 10-year
Effects of continuous renal replacement therapy on line- period：reasons and concerns for the future[J]. Antimicrob
zolid pharmacokinetic/pharmacodynamics：a systematic Resist Infect Control，2020，9（1）：156.
review[J]. Crit Care，2016，20（1）：374. [49] DENTAN C，FORESTIER E，ROUSTIT M，et al. Assess-
[38] BARRASA H，SORALUCE A，ISLAA，et al. Pharmacoki- ment of linezolid prescriptions in three French hospi-
netics of linezolid in critically ill patients on continuous tals[J]. Eur J Clin Microbiol Infect Dis，2017，36（7）：
renal replacement therapy：influence of residual renal 1133-1141.
function on PK/PD target attainment[J]. J Crit Care，2019， （下转第1536页）

·1524 · China Pharmacy 2022 Vol. 33 No. 12 中国药房 2022年第33卷第12期